Navigation Links
Cytokinetics Reports Additional Clinical Trials Data for Ispinesib

all of these trials; patients remain on treatment in the renal cell cancer trial. Data from the other trials have already been reported.

The NCI has completed patient treatment in a Phase I clinical trial designed to evaluate the safety, tolerability and pharmacokinetics of ispinesib on an alternative dosing schedule in patients with advanced solid tumors that have failed to respond to all standard therapies; data from this trial have already been reported. The NCI is continuing patient enrollment in a Phase I clinical trial designed to evaluate the safety, tolerability and pharmacokinetics of ispinesib on an alternative dosing schedule in patients with relapsed or refractory acute leukemia, chronic myelogenous leukemia in blast crisis, or advanced myelodysplastic syndromes. Data from this trial are expected in 2007.

Background on Mitotic Kinesin Inhibitors

Since their introduction over 40 years ago, anti-mitotic drugs (taxanes and vinca alkaloids) have advanced the treatment of cancer and are commonly used for the treatment of several tumor types. However, these drugs have demonstrated limited treatment benefit against certain cancers. In addition, these drugs target tubulin, a cytoskeletal protein involved not only in mitosis and cell proliferation, but also in other important cellular functions. Inhibition of these other cellular functions produces dose-limiting toxicities such as peripheral neuropathy, an impairment of peripheral nervous system function. Neuropathies are thought to result when these drugs interfere with the dynamics of microtubule filaments that are responsible for the long-distance transport of important cellular components within nerve cells.

Mitotic kinesins are essential to mitosis, and, unlike tubulin, appear to have no role in other cellular functions. Cytokinetics believes that drugs that inhibit KSP and CENP-E and other mitotic kinesins may represent the next generation of anti-mitotic cancer drugs
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cytokinetics Announces Non-clinical Data to be Presented at the 2007 AACR Annual Meeting
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:2/26/2015)...  Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical ... virus infections, today announced that Jonathan P. ... of Finance, a newly created role.  Mr. Freve ... including financial planning and reporting, accounting and risk ... , President and CEO. Mr. ...
(Date:2/26/2015)... Israel , Feb. 26, 2015 Integrity ... of the GlucoTrack ® model DF-F, a noninvasive  device ... Lutz Heinemann , Ph.D., will head its new ... opinion leaders in the field of Diabetes research, monitoring ... , Ph.D has been Chief Executive Officer and Head, ...
(Date:2/26/2015)... Feb. 26, 2015 The market for ... is estimated at 2.4 billion in 2014.   ... growth, government insurance, newly insured patients and updated ... and will continue to propel demand.  The healthcare market ... the market and interviews with IVD manufacturers and ...
Breaking Medicine Technology:Jonathan P. Freve, CPA, Joins Spring Bank Pharmaceuticals as Vice President of Finance 2Integrity Applications Names Prof. Lutz Heinemann to Advisory Board 2Integrity Applications Names Prof. Lutz Heinemann to Advisory Board 3Integrity Applications Names Prof. Lutz Heinemann to Advisory Board 4Kalorama: Led by Brazil, IVD Test Market in Latin America Exceeds 2 Billion 2Kalorama: Led by Brazil, IVD Test Market in Latin America Exceeds 2 Billion 3Kalorama: Led by Brazil, IVD Test Market in Latin America Exceeds 2 Billion 4
... Calif., Dec. 12, 2011 Since 1994, the Huntington ... of various specialties, has been providing expert medical care ... accepts almost every major health plan and is affiliated ... HMF is the group,s mission to provide a collaborative ...
... 12, 2011 /PRNewswire-iReach/ -- Thomas Ash was ... Ametros as executive vice president in February 2011. Prior ... compensation managed care industry. He served as vice president ... of national occupational health for Kaiser Permanente, division president ...
Cached Medicine Technology:The Huntington Medical Foundation -- Pasadena's Premier Medical Group 2Ametros Financial Names Thomas Ash as CEO 2
(Date:2/26/2015)... Francisco, CA (PRWEB) February 26, 2015 ... the American College of Traditional Chinese Medicine (ACTCM). ACTCM ... starting off with the Chinese New Year celebration and ... event schedule is as follows: , Sunday, March 1 ... 2:30 p.m., ACTCM celebrates the Chinese New Year with ...
(Date:2/26/2015)... When Cosmetic Town launched in 2012, its ... what will soon be, the cornerstone of work that ... of insight that will be accessible to the public, ... has maintained during its existence. Users have more data ... by visiting the Cosmetic Town Journal’s doctor’s page. There ...
(Date:2/26/2015)... 26, 2015 PartnerTech Inc . has ... Makers Awards finalist. , The Movers & ... in the manufacturing, processing, or distribution of tangible products and ... This annual event serves as Georgia’s largest local awards ... to draw more than 300 local industry and business leaders. ...
(Date:2/26/2015)... 26, 2015 Participants in the ... Working? What’s Not? What’s New? ,” will learn ... to achieve strong outcomes for duals-plan members and ... in the implementation phase of programs for Medicare-Medicaid ... Which ones need to be implemented in the ...
(Date:2/26/2015)... 26, 2015 The hip resurfacing procedure ... and Central Texas resident John Short to resume his active ... set out to climb Mt. Kilimanjaro, the highest free-standing mountain ... trafficking. , Starting in his late 20s, Short suffered from ... hip bones and sockets were bone on bone. , ...
Breaking Medicine News(10 mins):Health News:ACTCM Announces March Schedule of Events 2Health News:Cosmetic Town has now Recreated Itself by Adding New Features 2Health News:PartnerTech Named a Finalist for Gwinnett County Chamber of Commerce 2015 Movers & Makers Award 2Health News:PartnerTech Named a Finalist for Gwinnett County Chamber of Commerce 2015 Movers & Makers Award 3Health News:Upcoming AIS Virtual Conference Will Explain What Is and Is Not Working in Medicare-Medicaid Dual Eligibles Programs 2Health News:Hip Resurfacing at Texas Orthopedics Enables Patient to Climb Mt. Kilimanjaro 2Health News:Hip Resurfacing at Texas Orthopedics Enables Patient to Climb Mt. Kilimanjaro 3
... Association (AGA) Research Foundation has announced the 2011 ... Eli and Edythe Broad Foundation, the awards are ... digestive diseases. "At a time of ... are critical for the future of gastroenterology research, ...
... HealthDay Reporter , WEDNESDAY, June 8 (HealthDay News) -- ... the same time they,re having a uterine aspiration due to ... compared to women offered one later on, new research suggests. ... for IUDs inserted immediately after a uterine aspiration is higher ...
... of "pay-for-performance" bonuses to try to reduce racial and ethnic ... no evidence of the problem at any of the state,s ... questions about the effectiveness of the state,s novel approach. ... Health Affairs (June 9, 2011), found that racial and ...
... as an intrauterine device or IUD immediately following a first ... have an unintended pregnancy than those who delay getting an ... Oregon Health & Science University. The findings are ... Medicine . Research has shown that IUDs are safe, ...
... , WEDNESDAY, June 8 (HealthDay News) -- Jogging, ... protect the brain from "silent strokes," or small brain lesions ... of a future stroke, a new study suggests. "These ... they have been associated with an increased risk of falls ...
... of Sheffield have discovered valuable insight into how people ... in the UK. The team, from the University,s ... Lymphoma Research, Biotechnology and Biological Sciences Research Council (BBSRC) ... to that previously thought to be the cause of ...
Cached Medicine News:Health News:Outstanding high school students receive AGA Research Foundation Fellowship Awards 2Health News:It's Safe to Get IUD Right After Abortion, Miscarriage: Study 2Health News:It's Safe to Get IUD Right After Abortion, Miscarriage: Study 3Health News:Pioneering hospital pay-for-performance program falls short of its goals 2Health News:Immediate use of an IUD following abortion more likely to prevent unintended pregnancies 2Health News:Exercise May Protect the Brain From 'Silent Strokes' 2Health News:New research provides breakthrough in understanding common cancer 2
... FlexSure HP is a visually read, qualitative ... to H. pylori, a bacterium that grows ... peptic ulcer disease and some gastric cancers. ... whole blood or serum samples, provides the ...
Rapid Infectious Mononucleosis Heterophile Antibody (IgM) Test...
Unitary one step immuno-chromatographic assay for the qualitative detection of infectious mononucleosis heterophile antibodies in human serum, plasma or whole blood....
A simple, in-office test for the detection of mononucleosis. Easy to use with fast, accurate results within minutes....
Medicine Products: